HUTCHMED says savolitinib Phase II gastric cancer study posts 32.3% response rate

• HUTCHMED flagged new and updated oncology data scheduled for presentation at the 2026 ASCO Annual Meeting in Chicago from May 29 to June 2, 2026.
• A pivotal Phase II study of savolitinib in MET-amplified gastric or gastroesophageal junction cancer in China achieved its main efficacy goal, supporting a China filing that has already been accepted and moved into priority review.
• The ASCO program also includes additional analyses across fruquintinib and surufatinib studies in multiple tumor settings, extending the company’s evidence base for broader use and combination strategies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605212000PRIMZONEFULLFEED9725113) on May 22, 2026, and is solely responsible for the information contained therein.